A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

May 10, 2027

Study Completion Date

December 31, 2027

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

TT-00420 (tinengotinib)

oral

DRUG

AK104

intravenous

DRUG

AK112

intravenous

Trial Locations (1)

Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan